Literatur
-
1
Aurigemma G P, Gaasch W H.
Diastolic heart failure.
N Engl J Med.
2004;
351
1097-1105
-
2
Alchanatis M, Tourkohoriti G, Kosmas E N. et al .
Evidence for left ventricular dysfunction in patients with obstructive sleep apnoea syndrome.
Eur Respir J.
2002;
20
1239-1245
-
3
Bergstrom A, Andersson B, Edner M, Nylander E, Persson H, Dahlstom U.
Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function: Results of the Swedish Doppler-echocardiography study (SWEDIC).
Eur J Heart Fail.
2004;
6
453-461
-
4
Böger R H.
Wie wird die chronische Herzinsuffizienz heute tatsächlich behandelt.
Dtsch Med Wochenschr.
2002;
H34
1764
-
5
Böhm M.
Werden Herzglykoside zur Therapie der Herzinsuffizienz noch benötigt?.
Dtsch Med Wochenschr.
2002;
41
2133
-
6
Chobanian A V, Bakris G L, Black H R. et al .
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
Hypertension.
2003;
42
1206
-
7
Colucci W S.
Nesiritide for the treatment of decompensated heart failure.
J Card Fail.
2001;
7
92-100
-
8
Devereux R B, Dahlof B, Gerdts E. et al .
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Circulation.
2004;
110
1456-1462
-
9
Gandhi S K, Powers J C, Nomeier A M. et al .
The pathogenesis of acute pulmonary edema associated with hypertension.
N Engl J Med.
2001;
344
17-22
-
10
Hunt S A, Baker D W, Chin M H. et al .
ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: executive summary.
Circulation.
2001;
104
2996-3007
-
11
Kindermann M, Janzen I, Hennen B, Böhm M.
Chronische Herzinsuffizienz - Therapie.
Dtsch Med Wochenschr.
2002;
H21
1139
-
12
Remme W J, Swedberg K.
Guidelines for the diagnosis and treatment of chronic heart failure.
Eur Heart J.
2001;
22
1527-1560
-
13
Setaro J F, Zaret B L, Schulman D S. et al .
Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance.
Am J Cardiol.
1990;
66
981-986
-
14
The Digitalis Investigation Group .
The effect of digoxin on mortality and morbidity in patients with heart failure.
N Eng J Med.
1997;
336
525-533
-
15
Weber K T, Brilla C G.
Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosteron-system.
Circulation.
1991;
83
1849-1865
-
16
Yusuf S, Pfeffer M A, Swedberg K. et al .
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.
Lancet.
2003;
362
777-781
-
17
Zannad F, Allo F, Dousset B. et al .
Limitation of the extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
Circulation.
2000;
102
2700-2706
-
18
Zile M R, Brutsaert D L.
New concepts in diastolic dysfunction and diastolic heart failure: Part II. Causal Mechanisms and Treatment.
Circulation.
2002;
105
1503-1508
-
19
Hader C, Sanner B, Rasche K.
Das obstruktive Schlafapnoe-Syndrom - Diagnostik.
Dtsch Med Wochenschr.
2004;
11
566-569
-
20
Sanner B, Hader C, Rasche K.
Das obstruktive Schlafapnoe-Syndrom - Therapie.
Dtsch Med Wochenschr.
2004;
11
570-572
Prof. Dr. med. Burkert Pieske
Universitätsklinikum Göttingen, Abteilung Kardiologie und Pneumologie
Robert Koch-Straße 40
37035 Göttingen
Telefon: 0551/398925
Fax: 0551/3919127
eMail: pieske@med.uni-goettingen.de
